Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital
Launched by MOHAMED NASR · Sep 15, 2024
Trial Information
Current as of September 10, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the connection between a condition called axial spondylosis arthritis and inflammatory bowel disease (IBD), which includes conditions like ulcerative colitis and Crohn's disease. The study aims to see how well a type of treatment called TNF inhibitors works for patients with IBD who also have symptoms of axial spondylosis arthritis, such as long-term lower back pain that improves with exercise.
To be considered for this trial, participants must be adults aged between 65 and 74 years who have been diagnosed with IBD and are currently being treated with TNF inhibitors. They should also have specific symptoms related to axial spondylosis arthritis. The trial will collect various health-related information from participants, including their medical history and the effectiveness of their current treatments. If you or someone you know has IBD and meets these criteria, this trial could provide valuable insights into managing both conditions.
Gender
ALL
Eligibility criteria
- • Inclusion Criteria:IBD patients (ulcerative colitis , Crohn\'s disease )on TNF inhibitors Data collected included SPA and IBD variables, demographics, concurrent medications, co-morbidities and autoimmune serology.
- • They fulfil criteria of axial SPA Clinical Criteria 12 Low back pain ≥ 3 months, improved by exercise and not relieved by rest Limitation of lumbar spine in sagittal and frontal planes Limitation of chest expansion (relative to normal values corrected for age and sex) Radiological Criteria Bilateral grade 2-4 sacroiliitis, or; Unilateral 3-4 sacroiliitis Assessment of disease activity of SPA 13 Patient fulfill criteria of IBD 14 Assessment of IBD activity (Esr , CRP ,Faecal calprotectin , CBC , albumin ,endoscopy, histopathology) Mayo score for U.C Crohn\'s disease Activity index
- • Exclusion Criteria: Other autoimmune disease , DM, LCF ,CRF ,Malignancy , Mechanical low back pain, Fracture , Spondylolisthesis , Spine tumores , Kidney stones .
- • -
About Mohamed Nasr
Mohamed Nasr is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on rigorous scientific methodology and ethical standards, the organization conducts clinical trials across a range of therapeutic areas, ensuring compliance with regulatory requirements and fostering collaboration with healthcare professionals and stakeholders. By leveraging cutting-edge technology and a patient-centered approach, Mohamed Nasr aims to contribute significantly to the development of safe and effective treatments, ultimately enhancing healthcare delivery and patient quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Salwa salaheldin elgendi, professor doctor
Study Director
Assiut University
hossam Mahmoud AbdulWahab, assistant professor
Principal Investigator
Assiut University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported